Flagship Ventures 2007 General Partner LLC
CIK 0001508053 Name as filed on the most recent filing
Filed as Flagship Ventures 2007 General Partner LLC (10)
37 transaction lines · from 10 filings · filed 2013-03-27 to 2019-05-15 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Axcella Health Inc. 1 filings
- ISSUER Eleven Biotherapeutics, Inc. 5 filings
- ISSUER Seres Therapeutics, Inc. 1 filings
- ISSUER Receptos, Inc. 2 filings
- ISSUER Tetraphase Pharmaceuticals Inc 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2019-05-13 |
Axcella Health Inc. AXLA |
P, Open-market purchase | 500,000 acquired | 20.00 | 10,000,000.00 | Form 4, filing 0001104659-19-029735 | |
| 2016-09-23 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 41,178 disposed | 3.10 | 127,651.80 | Form 4, filing 0001012975-16-001507 | |
| 2016-09-23 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 12,482 disposed | 3.16 | 39,443.12 | Form 4, filing 0001012975-16-001507 | |
| 2016-09-23 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 10,293 disposed | 3.10 | 31,908.30 | Form 4, filing 0001012975-16-001507 | |
| 2016-09-23 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 3,118 disposed | 3.16 | 9,852.88 | Form 4, filing 0001012975-16-001507 | |
| 2016-09-22 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 188,367 disposed | 3.17 | 597,123.39 | Form 4, filing 0001012975-16-001507 | |
| 2016-09-22 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 112,731 disposed | 3.18 | 358,484.58 | Form 4, filing 0001012975-16-001507 | |
| 2016-09-22 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 47,090 disposed | 3.17 | 149,275.30 | Form 4, filing 0001012975-16-001507 | |
| 2016-09-22 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 28,163 disposed | 3.18 | 89,558.34 | Form 4, filing 0001012975-16-001507 | |
| 2016-09-21 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 258,214 disposed | 3.75 | 968,302.50 | Form 4, filing 0001012975-16-001505 | |
| 2016-09-21 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 64,509 disposed | 3.75 | 241,908.75 | Form 4, filing 0001012975-16-001505 | |
| 2016-09-20 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 43,139 disposed | 3.39 | 146,241.21 | Form 4, filing 0001012975-16-001505 | |
| 2016-09-20 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 10,778 disposed | 3.39 | 36,537.42 | Form 4, filing 0001012975-16-001505 | |
| 2016-09-19 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 7,761 disposed | 3.31 | 25,688.91 | Form 4, filing 0001012975-16-001505 | |
| 2016-09-19 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 1,939 disposed | 3.31 | 6,418.09 | Form 4, filing 0001012975-16-001505 | |
| 2016-09-15 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 2,145 disposed | 4.16 | 8,923.20 | Form 4, filing 0001012975-16-001503 | |
| 2016-09-15 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 536 disposed | 4.16 | 2,229.76 | Form 4, filing 0001012975-16-001503 | |
| 2016-09-14 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 35,209 disposed | 4.18 | 147,173.62 | Form 4, filing 0001012975-16-001503 | |
| 2016-09-14 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 8,802 disposed | 4.18 | 36,792.36 | Form 4, filing 0001012975-16-001503 | |
| 2016-09-07 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 52,985 disposed | 4.51 | 238,962.35 | Form 4, filing 0001012975-16-001495 | |
| 2016-09-07 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 32,597 disposed | 4.51 | 147,012.47 | Form 4, filing 0001012975-16-001495 | |
| 2016-09-07 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 8,145 disposed | 4.51 | 36,733.95 | Form 4, filing 0001012975-16-001495 | |
| 2016-09-06 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 20,221 disposed | 4.63 | 93,623.23 | Form 4, filing 0001012975-16-001495 | |
| 2016-09-06 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 12,441 disposed | 4.63 | 57,601.83 | Form 4, filing 0001012975-16-001495 | |
| 2016-09-06 |
Eleven Biotherapeutics, Inc. EBIO |
S, Open-market sale | 3,108 disposed | 4.63 | 14,390.04 | Form 4, filing 0001012975-16-001495 | |
| 2016-05-25 |
Seres Therapeutics, Inc. MCRB |
S, Open-market sale | 599,297 disposed | 27.60 | 16,540,597.20 | Form 4, filing 0001012975-16-001264 | |
| 2016-05-25 |
Seres Therapeutics, Inc. MCRB |
S, Open-market sale | 320,562 disposed | 27.60 | 8,847,511.20 | Form 4, filing 0001012975-16-001264 | |
| 2016-05-25 |
Seres Therapeutics, Inc. MCRB |
S, Open-market sale | 80,141 disposed | 27.60 | 2,211,891.60 | Form 4, filing 0001012975-16-001264 | |
| 2014-02-11 |
Eleven Biotherapeutics, Inc. EBIO |
P, Open-market purchase | 214,095 acquired | 10.00 | 2,140,950.00 | Form 4, filing 0001181431-14-006845 | |
| 2014-02-11 |
Eleven Biotherapeutics, Inc. EBIO |
P, Open-market purchase | 131,722 acquired | 10.00 | 1,317,220.00 | Form 4, filing 0001181431-14-006845 | |
| 2014-02-11 |
Eleven Biotherapeutics, Inc. EBIO |
P, Open-market purchase | 32,912 acquired | 10.00 | 329,120.00 | Form 4, filing 0001181431-14-006845 | |
| 2013-11-18 |
Receptos, Inc. RCPT |
S, Open-market sale | 20,300 disposed | 24.09 | 489,027.00 | Form 4, filing 0001181431-13-059544 | |
| 2013-11-15 |
Receptos, Inc. RCPT |
S, Open-market sale | 54,000 disposed | 24.20 | 1,306,800.00 | Form 4, filing 0001181431-13-059544 | |
| 2013-11-15 |
Receptos, Inc. RCPT |
S, Open-market sale | 904 disposed | 25.10 | 22,690.40 | Form 4, filing 0001181431-13-059544 | |
| 2013-11-14 |
Receptos, Inc. RCPT |
S, Open-market sale | 155,583 disposed | 25.03 | 3,894,242.49 | Form 4, filing 0001181431-13-059544 | |
| 2013-05-14 |
Receptos, Inc. RCPT |
P, Open-market purchase | 107,142 acquired | 14.00 | 1,499,988.00 | Form 4, filing 0001104659-13-041517 | |
| 2013-03-25 |
Tetraphase Pharmaceuticals Inc TTPH |
P, Open-market purchase | 491,824 acquired | 7.00 | 3,442,768.00 | Form 4, filing 0001181431-13-019227 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Flagship Ventures 2007 General Partner LLC, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001508053
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6